4.7 Article

Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 25, Issue 7, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2018.10.016

Keywords

Biosafety; Diagnosis of infections; Serological tests; Triton X-100; Virus inactivation

Ask authors/readers for more resources

Objectives: Highly pathogenic viruses such as EBOV are a threat to routine laboratory workers. Inactivation procedures with Triton X-100 0.1% and/or heat are currently recommended, but have unknown effects on the accuracy of serological testing. Furthermore, virus inactivation by Triton X-100 0.1% was shown to be ineffective in serum. This study aimed to demonstrate virus inactivation in serum by Triton X-100 1% and maintained accuracy of serological testing. Methods: A panel of 19 serological tests was run on patient serum samples after treatment with Triton X-100 1%, 0.1%, and 0.1% + heat inactivation at 60 degrees C for 1 h. Mean differences between measurements (bias) were calculated applying the Bland-Altman method. To determine effectiveness of virus inactivation, herpes simplex virus 1 (HSV-1) was spiked into medium containing 90% or 1% serum, and treated with Triton X-100 0.1% or 1%. Infectious titres were then determined on Vero cells. Results: Serological measurements showed good agreement between controls and samples treated with Triton X-100 0.1% and 1%, with an estimated bias of 0.6 +/- 9.2% (n = 258) and -0.1 +/- 18.6% (n = 174), respectively. Discordant qualitative results were rare. Conversely, heat inactivation alone and combined with Triton X-100 0.1% triggered a bias of 17.5 +/- 66.4% (n = 200) and 37.9 +/- 79.8% (n = 160), respectively. Triton X-100 1% completely inactivated HSV-1 in 1% and 90% serum while Triton X-100 0.1% failed to do so in 90% serum. Conclusions: Unlike heat inactivation, Triton X-100 1% enabled accurate serological testing and completely inactivated HSV-1 in serum. This simple method could allow safe routine serological diagnostics in high-risk patients. (C) 2018 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Microbiology

Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection

Rami Sommerstein, Lukas Flatz, Melissa M. Remy, Pauline Malinge, Giovanni Magistrelli, Nicolas Fischer, Mehmet Sahin, Andreas Bergthaler, Sebastien Igonet, Jan ter Meulen, Dorothee Rigo, Paolo Meda, Nadia Rabah, Bruno Coutard, Thomas A. Bowden, Paul-Henri Lambert, Claire-Anne Siegrist, Daniel D. Pinschewer

PLOS PATHOGENS (2015)

Article Immunology

Cerebrospinal fluid CXCL13 as a diagnostic marker of neuroborreliosis in children: a retrospective case-control study

M. M. Remy, N. Schobi, L. Kottanattu, S. Pfister, A. Duppenthaler, F. Suter-Riniker

JOURNAL OF NEUROINFLAMMATION (2017)

Article Immunology

The Role of CD80/CD86 in Generation and Maintenance of Functional Virus-Specific CD8+ T Cells in Mice Infected with Lymphocytic Choriomeningitis Virus

Mirjana Grujic, Christina Bartholdy, Melissa Remy, Daniel D. Pinschewer, Jan P. Christensen, Allan R. Thomsen

JOURNAL OF IMMUNOLOGY (2010)

Article Microbiology

The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever

Mehmet Sahin, Melissa M. Remy, Doron Merkler, Daniel D. Pinschewer

Summary: The FDA-approved JAK inhibitor Ruxolitinib showed potential in the treatment of Arenaviruses hemorrhagic fever (AVHF) by preventing terminal disease and microvascular leak symptoms. In addition to IFN-gamma-induced iNOS pathway, other druggable pathways contribute essentially to AVHF and are amenable to host-directed therapy.

MICROORGANISMS (2021)

Article Cell Biology

Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors

Mehmet Sahin, Melissa M. Remy, Benedict Fallet, Rami Sommerstein, Marianna Florova, Anna Langner, Katja Klausz, Tobias Straub, Mario Kreutzfeldt, Ingrid Wagner, Cinzia T. Schmidt, Pauline Malinge, Giovanni Magistrelli, Shozo Izui, Hanspeter Pircher, J. Sjef Verbeek, Doron Merkler, Matthias Peipp, Daniel D. Pinschewer

Summary: In this study, the role of antibody multivalency in protecting neutralizing and non-neutralizing antibodies in virus-infected mice was investigated. The results showed that antibody bivalency enables the tethering of virions to the infected cell surface and inhibits virion release, independently of Fc gamma receptor interactions. The protection in mice was found to be correlated with the virus-release-inhibiting activity of the antibodies rather than their neutralizing capacity. These findings provide insights into the evolutionary conservation of antibody multivalency and have implications for vaccine development targeting non-neutralizing antibodies.

CELL REPORTS (2022)

Review Biochemistry & Molecular Biology

Biomolecules capturing live bacteria from clinical samples

Michele Sorgenfrei, Lea M. Hurlimann, Melissa M. Remy, Peter M. Keller, Markus A. Seeger

Summary: This article summarizes various biomolecules used for capturing live bacteria, including immune proteins, antibodies, aptamers, phage proteins, and antimicrobial peptides. The article also discusses the potential use of nanobodies targeting conserved surface-accessible proteins as promising biomolecules for pathogen capture.

TRENDS IN BIOCHEMICAL SCIENCES (2022)

Article Microbiology

Interferon-γ-Driven iNOS: A Molecular Pathway to Terminal Shock in Arenavirus Hemorrhagic Fever

Melissa M. Remy, Mehmet Sahin, Lukas Flatz, Tommy Regen, Lifen Xu, Mario Kreutzfeldt, Benedict Fallet, Camille Doras, Toni Rieger, Lukas Bestmann, Uwe-Karsten Hanisch, Beat A. Kaufmann, Doron Merkler, Daniel D. Pinschewer

CELL HOST & MICROBE (2017)

Article Immunology

Interferon-driven deletion of antiviral B cells at the onset of chronic infection

Benedict Fallet, Kerstin Narr, Yusuf I. Ertuna, Melissa Remy, Rami Sommerstein, Karen Cornille, Mario Kreutzfeldt, Nicolas Page, Gert Zimmer, Florian Geier, Tobias Straub, Hanspeter Pircher, Kevin Larimore, Philip D. Greenberg, Doron Merkler, Daniel D. Pinschewer

SCIENCE IMMUNOLOGY (2016)

No Data Available